BUZZ-SpyGlass surges in Nasdaq debut after $150 million IPO

SpyGlass Pharma, Inc. +2.72% Pre

SpyGlass Pharma, Inc.

SGP

24.52

24.52

+2.72%

0.00% Pre

Updates

** Biopharmaceutical company SpyGlass Pharma's SGP.O shares surge as much as 50% in Nasdaq debut

** Stock opened at $24 apiece vs $16 IPO price

** SGP sold ~9.4 million shares within marketed range of $15 and $17 to raise $150 million

** Founded in 2019 by Malik Kahook and Glenn Sussman, SGP is building a portfolio of drug delivery systems to provide long-acting therapy for chronic eye diseases

** SGP's lead program, the BIM-IOL system, integrates glaucoma treatment into standard cataract surgery

** Jefferies, Leerink Partners, Citigroup and Stifel were joint book-running managers for offering


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.